ClinicalTrials.gg
CompletedNCT01786512COSMIC-HFUpdated Aug 12, 2021Results posted

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

A Phase 2 interventional study of Omecamtiv Mecarbil Matrix F1 Formulation and Omecamtiv Mecarbil Matrix F2 Formulation in Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction and Chronic Heart Failure, sponsored by Cytokinetics. Completed at 101 sites in 13 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-08-12.

Sponsored by Cytokinetics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
544
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies in Ventricular Dysfunction, Left with a site in United States — 15 open to participants now, 21 under way, 3 of them phase 3. Ventricular Dysfunction, Left · United States.

Enrollment
9th of 57
544 · median 87
Started
2013
with 3 others
Phase 2
12 of 84
1 open now
Registered
35th of 84
by date
Lead sponsor
2 of 84
Cytokinetics

Among the 84 studies in Ventricular Dysfunction, Left with a site in United States, this one is the 9th largest by enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2013, is one of 12 in phase 2, and was the 35th registered.

Ventricular Dysfunction, Left

260 studies on the registry are indexed under Ventricular Dysfunction, Left; 57 are open to participants now.

Browse Ventricular Dysfunction, Left studies →

Open to participants now

15 of the 84 studies in Ventricular Dysfunction, Left with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Ventricular Dysfunction, Left studies recruiting now, 21 (55%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Ventricular Dysfunction, Left with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of this study are (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in adults with heart failure and left ventricular systolic dysfunction and (ii) to characterize its pharmacokinetics (PK) over 20 weeks of treatment.

Read the detailed description

Omecamtiv mecarbil (AMG 423, CK-1827452) is a novel small molecule that increases cardiac contractility by selectively and directly activating the enzymatic domain of cardiac myosin heavy chain, the force-generating motor protein of the cardiac sarcomere. This is a randomized, placebo-controlled, multicenter, phase 2 study, consisting of a dose escalation phase to select 1 of 3 omecamtiv mecarbil oral formulations in 2 dose escalation cohorts, followed by an expansion phase to evaluate 20 weeks of administration of the selected omecamtiv mecarbil formulation at 2 target dose levels, compared with placebo.

This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.

03

Conditions studied

  • Modified Release Oral Formulation
  • Left Ventricular Systolic Dysfunction
  • Chronic Heart Failure
  • History of Chronic Heart Failure
  • Left Ventricular Ejection Fraction
  • Pharmacokinetics
  • Echocardiogram

Keywords

  • Pharmacokinetics
  • Omecamtiv mecarbil
  • AMG 423
  • Double-blind
  • Randomized
  • Placebo-controlled
  • Oral forumlation
  • CK-1827452
  • Cardiac myosin activator
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of chronic heart failure (HF), defined as requiring treatment for HF for a minimum of 4 weeks prior to screening
  • Treated with stable, optimal pharmacological therapy for ≥ 4 weeks
  • History of (LVEF) ≤ 40%
  • Elevated N-terminal prohormone B-type natriuretic peptide (NT-proBNP)

Exclusion criteria

Exclusion criteria:

  • Severe uncorrected valvular heart disease
  • Hospitalization within 30 days prior to enrollment
  • Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or congenital heart disease
  • Acute myocardial infarction, unstable angina or persistent angina at rest within 30 days prior to randomization
  • Systolic blood pressure > 160 mmHg or \< 90 mmHg or diastolic blood pressure > 90 mmHg
  • Total ≥ 2 x (ULN); (AST) or alanine aminotransferase (ALT) ≥ 3 x ULN
  • Estimated (eGFR) \< 30 mL/min/1.73m\^2
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
544 participants (actual)

Study arms

  • Placebo comparator
    Dose-escalation Cohort 1: Placebo

    Participants received placebo tablets twice a day (BID) for 7 days.

    Drug: Placebo

  • Experimental
    Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1

    Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days.

    Drug: Omecamtiv Mecarbil Matrix F1 Formulation

  • Experimental
    Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2

    Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days.

    Drug: Omecamtiv Mecarbil Matrix F2 Formulation

  • Experimental
    Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2

    Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days.

    Drug: Omecamtiv Mecarbil Swellable Core Technology F2

  • Placebo comparator
    Dose-escalation Cohort 2: Placebo

    Participants received placebo tablets twice a day for 7 days.

    Drug: Placebo

  • Experimental
    Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1

    Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days.

    Drug: Omecamtiv Mecarbil Matrix F1 Formulation

  • Experimental
    Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2

    Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days.

    Drug: Omecamtiv Mecarbil Matrix F2 Formulation

  • Experimental
    Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2

    Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days.

    Drug: Omecamtiv Mecarbil Swellable Core Technology F2

  • Placebo comparator
    Expansion Phase: Placebo

    Participants received placebo tablets twice a day for 20 weeks.

    Drug: Placebo

  • Experimental
    Expansion Phase: Omecamtiv Mecarbil 25 mg M-F1

    Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks.

    Drug: Omecamtiv Mecarbil Matrix F1 Formulation

  • Experimental
    Expansion Phase: OM M-F1 PK-based Titration

    All participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL.

    Drug: Omecamtiv Mecarbil Matrix F1 Formulation

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)

    Time frame: Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours, and 7 days post-dose.

  2. Dose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)

    Time frame: Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours, and 7 days post-dose.

  3. Dose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7

    Time frame: Day 7 at predose

  4. Dose Escalation Phase: Area Under the Plasma Concentration-time Curve for a Dosing Interval of 12 Hours Post Dose (AUC12) for Omecamtiv Mecarbil

    Time frame: Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose

  5. Expansion Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing

    Time frame: Predose (before morning dose) at weeks 2, 8, 12, 16, and 20

  6. Expansion Phase: Maximum Observed Plasma Concentration of Omecamtiv Mecarbil

    Time frame: Weeks 2 and 12 at predose and 1, 2, 4, 6, and 8 hours post-dose.

Secondary outcomes

  1. Expansion Phase: Change From Baseline in Systolic Ejection Time (SET) at Week 20

    Systolic ejection time was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.

    Time frame: Baseline and week 20

  2. Expansion Phase: Change From Baseline in Stroke Volume at Week 20

    Stroke volume was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.

    Time frame: Baseline and week 20

  3. Expansion Phase: Change From Baseline in Left Ventricular End Systolic Diameter (LVESD) at Week 20

    LVESD was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.

    Time frame: Baseline and week 20

  4. Expansion Phase: Change From Baseline in Left Ventricular End Diastolic Diameter (LVEDD) at Week 20

    LVEDD was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.

    Time frame: Baseline and week 20

  5. Expansion Phase: Change From Baseline in Heart Rate at Week 20

    Heart rate was measured using electrocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.

    Time frame: Baseline and week 20

  6. Expansion Phase: Change From Baseline in N-terminal Prohormone B-type Natriuretic Peptide (NT-proBNP) at Week 20

    Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.

    Time frame: Baseline and week 20

  7. Dose Escalation Phase: Number of Participants With Treatment-emergent Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events. Each adverse event was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, and Grade 4 = life-threatening AE. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event

    Time frame: From first dose of study drug to 4 weeks after last dose; treatment duration was 7 days in the dose escalation phase.

  8. Expansion Phase: Number of Participants With Treatment-emergent Adverse Events

    An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events. Each adverse event was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, and Grade 4 = life-threatening AE. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event

    Time frame: From first dose of study drug until 4 weeks after last dose; treatment duration was 20 weeks in the expansion phase.

07

Results

Posted May 17, 2021

Participant flow

Participants with chronic heart failure treated with stable, optimal pharmacological therapy for ≥ 4 weeks were enrolled from February 2013 to March 2015 at 86 centers in 13 countries in Europe, Australia, and North America. The study consisted of a dose-escalation phase to select 1 of 3 omecamtiv mecarbil (OM) oral formulations in 2 dose cohorts, and an expansion phase to evaluate 20 weeks of treatment with the selected formulation at 2 target dose levels, compared with placebo.

Participant flow — Overall Study
MilestoneDose-escalation Cohort 1: PlaceboDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: PlaceboDose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2Expansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based Titration
Started1111141310111214149150149
Received study treatment1110141310111114149150146
Completed1110141310111114145145137
Not completed010000104512
Withdrew: Lost to follow-up00000000010
Withdrew: Decision by sponsor00000000002
Withdrew: Withdrawal by subject01000010037
Withdrew: Death00000000413

Outcome measures

PrimaryDose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)
Time frame:
Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours, and 7 days post-dose.
Reported as:
Mean · ng/mL
Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)
ng/mLDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2
Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)193 ± 58.8201 ± 94.4171 ± 53.8492 ± 115502 ± 138601 ± 204
PrimaryDose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)
Time frame:
Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours, and 7 days post-dose.
Reported as:
Mean · hours
Dose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)
hoursDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2
Dose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)3.9 ± 4.42.0 ± 1.24.2 ± 1.92.6 ± 2.42.2 ± 1.84.6 ± 2.3
PrimaryDose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7
Time frame:
Day 7 at predose
Reported as:
Mean · ng/mL
Dose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7
ng/mLDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2
Dose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7157 ± 63.7137 ± 56.8134 ± 54.7376 ± 170395 ± 108476 ± 234
PrimaryDose Escalation Phase: Area Under the Plasma Concentration-time Curve for a Dosing Interval of 12 Hours Post Dose (AUC12) for Omecamtiv Mecarbil
Time frame:
Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose
Reported as:
Mean · ng*hr/mL
Dose Escalation Phase: Area Under the Plasma Concentration-time Curve for a Dosing Interval of 12 Hours Post Dose (AUC12) for Omecamtiv Mecarbil
ng*hr/mLDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2
Dose Escalation Phase: Area Under the Plasma Concentration-time Curve for a Dosing Interval of 12 Hours Post Dose (AUC12) for Omecamtiv Mecarbil2030 ± 6582000 ± 10201740 ± 5865070 ± 10605010 ± 11606550 ± 2340
PrimaryExpansion Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing
Time frame:
Predose (before morning dose) at weeks 2, 8, 12, 16, and 20
Reported as:
Mean · ng/mL
Expansion Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing
ng/mLExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based Titration
Week 2174 ± 62.2179 ± 68.8
Week 8156 ± 69.1161 ± 74.4
Week 12165 ± 67.9263 ± 116
Week 16155 ± 69.0240 ± 120
Week 20149 ± 71.2239 ± 118
PrimaryExpansion Phase: Maximum Observed Plasma Concentration of Omecamtiv Mecarbil
Time frame:
Weeks 2 and 12 at predose and 1, 2, 4, 6, and 8 hours post-dose.
Reported as:
Mean · ng/mL
Expansion Phase: Maximum Observed Plasma Concentration of Omecamtiv Mecarbil
ng/mLExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based Titration
Week 2212 ± 70.4212 ± 81.0
Week 12200 ± 71.1318 ± 129
SecondaryExpansion Phase: Change From Baseline in Systolic Ejection Time (SET) at Week 20

Systolic ejection time was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.

Time frame:
Baseline and week 20
Reported as:
Least squares mean · seconds
Expansion Phase: Change From Baseline in Systolic Ejection Time (SET) at Week 20
secondsExpansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based Titration
Expansion Phase: Change From Baseline in Systolic Ejection Time (SET) at Week 200.0000 ± 0.00250.0112 ± 0.00240.0250 ± 0.0026
Statistical analysis
  • Expansion Phase: Placebo vs Expansion Phase: Omecamtiv Mecarbil 25 mg · Repeated Measures · p = 0.0007 · Treatment difference: 0.0112 · 95% CI 0.0047 to 0.0176Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
  • Expansion Phase: Placebo vs Expansion Phase: OM PK-based Titration · Repeated Measures · p = <0.0001 · Treatment difference: 0.0250 · 95% CI 0.0184 to 0.0315Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
SecondaryExpansion Phase: Change From Baseline in Stroke Volume at Week 20

Stroke volume was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.

Time frame:
Baseline and week 20
Reported as:
Least squares mean · mL
Expansion Phase: Change From Baseline in Stroke Volume at Week 20
mLExpansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based Titration
Expansion Phase: Change From Baseline in Stroke Volume at Week 20-1.05 ± 1.183.53 ± 1.162.58 ± 1.19
Statistical analysis
  • Expansion Phase: Placebo vs Expansion Phase: Omecamtiv Mecarbil 25 mg · Repeated Measures · p = 0.0036 · Treatment difference: 4.58 · 95% CI 1.50 to 7.65Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
  • Expansion Phase: Placebo vs Expansion Phase: OM PK-based Titration · Repeated Measures · p = 0.0217 · Treatment difference: 3.63 · 95% CI 0.53 to 6.72Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
SecondaryExpansion Phase: Change From Baseline in Left Ventricular End Systolic Diameter (LVESD) at Week 20

LVESD was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.

Time frame:
Baseline and week 20
Reported as:
Least squares mean · cm
Expansion Phase: Change From Baseline in Left Ventricular End Systolic Diameter (LVESD) at Week 20
cmExpansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based Titration
Expansion Phase: Change From Baseline in Left Ventricular End Systolic Diameter (LVESD) at Week 20-0.242 ± 0.043-0.322 ± 0.044-0.421 ± 0.045
Statistical analysis
  • Expansion Phase: Placebo vs Expansion Phase: Omecamtiv Mecarbil 25 mg · Repeated Measures · p = 0.1732 · Treatment difference: -0.079 · 95% CI -0.194 to 0.035Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
  • Expansion Phase: Placebo vs Expansion Phase: OM PK-based Titration · Repeated Measures · p = 0.0027 · Treatment difference: -0.179 · 95% CI -0.295 to -0.062Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
SecondaryExpansion Phase: Change From Baseline in Left Ventricular End Diastolic Diameter (LVEDD) at Week 20

LVEDD was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.

Time frame:
Baseline and week 20
Reported as:
Least squares mean · cm
Expansion Phase: Change From Baseline in Left Ventricular End Diastolic Diameter (LVEDD) at Week 20
cmExpansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based Titration
Expansion Phase: Change From Baseline in Left Ventricular End Diastolic Diameter (LVEDD) at Week 200.089 ± 0.0380.023 ± 0.038-0.040 ± 0.040
Statistical analysis
  • Expansion Phase: Placebo vs Expansion Phase: Omecamtiv Mecarbil 25 mg · Repeated Measures · p = 0.1899 · Treatment difference: -0.067 · 95% CI -0.166 to 0.033Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
  • Expansion Phase: Placebo vs Expansion Phase: OM PK-based Titration · Repeated Measures · p = 0.0128 · Treatment difference: -0.129 · 95% CI -0.231 to -0.028Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
SecondaryExpansion Phase: Change From Baseline in Heart Rate at Week 20

Heart rate was measured using electrocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.

Time frame:
Baseline and week 20
Reported as:
Least squares mean · bpm
Expansion Phase: Change From Baseline in Heart Rate at Week 20
bpmExpansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based Titration
Expansion Phase: Change From Baseline in Heart Rate at Week 200.57 ± 0.79-0.77 ± 0.79-2.40 ± 0.81
Statistical analysis
  • Expansion Phase: Placebo vs Expansion Phase: Omecamtiv Mecarbil 25 mg · Repeated Measures · p = 0.2177 · Treatment difference: -1.34 · 95% CI -3.47 to 0.79Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
  • Expansion Phase: Placebo vs Expansion Phase: OM PK-based Titration · Repeated Measures · p = 0.0070 · Treatment difference: -2.97 · 95% CI -5.12 to -0.81Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
SecondaryExpansion Phase: Change From Baseline in N-terminal Prohormone B-type Natriuretic Peptide (NT-proBNP) at Week 20

Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.

Time frame:
Baseline and week 20
Reported as:
Least squares mean · pg/mL
Expansion Phase: Change From Baseline in N-terminal Prohormone B-type Natriuretic Peptide (NT-proBNP) at Week 20
pg/mLExpansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based Titration
Expansion Phase: Change From Baseline in N-terminal Prohormone B-type Natriuretic Peptide (NT-proBNP) at Week 20502 ± 257-319 ± 257-468 ± 262
Statistical analysis
  • Expansion Phase: Placebo vs Expansion Phase: Omecamtiv Mecarbil 25 mg · Repeated Measures · p = 0.0205 · Treatment difference: -822 · 95% CI -1516 to -127Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
  • Expansion Phase: Placebo vs Expansion Phase: OM PK-based Titration · Repeated Measures · p = 0.0069 · Treatment difference: -970 · 95% CI -1672 to -268Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
SecondaryDose Escalation Phase: Number of Participants With Treatment-emergent Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events. Each adverse event was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, and Grade 4 = life-threatening AE. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event

Time frame:
From first dose of study drug to 4 weeks after last dose; treatment duration was 7 days in the dose escalation phase.
Reported as:
Count of participants · Participants
Dose Escalation Phase: Number of Participants With Treatment-emergent Adverse Events
ParticipantsDose-escalation Cohort 1: PlaceboDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: PlaceboDose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2
Any treatment-emergent adverse event (TEAE)42661935
TEAE Grade ≥ 201111511
TEAE Grade ≥ 300100201
TEAE Grade ≥ 400000000
Serious adverse events00100201
TEAE leading to discontinuation of study drug00000200
Fatal adverse events00000000
SecondaryExpansion Phase: Number of Participants With Treatment-emergent Adverse Events

An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events. Each adverse event was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, and Grade 4 = life-threatening AE. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event

Time frame:
From first dose of study drug until 4 weeks after last dose; treatment duration was 20 weeks in the expansion phase.
Reported as:
Count of participants · Participants
Expansion Phase: Number of Participants With Treatment-emergent Adverse Events
ParticipantsExpansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based Titration
Any treatment-emergent adverse event (TEAE)919295
TEAE Grade ≥ 2626061
TEAE Grade ≥ 3342831
TEAE Grade ≥ 45811
Serious adverse events303632
TEAEs leading to discontinuation of study drug12812
Fatal adverse events413

Adverse events

Collected over From first dose of study drug to 4 weeks after last dose; treatment duration was 7 days in the dose escalation phase and 20 weeks in the expansion phase.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose-escalation Cohort 1: Placebo—0/11 (0%)4/11 (36.4%)
Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1—0/10 (0%)2/10 (20%)
Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2—1/14 (7.1%)5/14 (35.7%)
Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2—0/13 (0%)6/13 (46.2%)
Dose-escalation Cohort 2: Placebo—0/10 (0%)1/10 (10%)
Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1—2/11 (18.2%)8/11 (72.7%)
Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2—0/11 (0%)3/11 (27.3%)
Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2—1/14 (7.1%)4/14 (28.6%)
Expansion Phase: Placebo—30/149 (20.1%)48/149 (32.2%)
Expansion Phase: Omecamtiv Mecarbil 25 mg—36/150 (24%)51/150 (34%)
Expansion Phase: OM PK-based Titration—32/146 (21.9%)48/146 (32.9%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventDose-escalation Cohort 1: PlaceboDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: PlaceboDose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2Expansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based Titration
Angina unstableCardiac disorders0/110/100/140/130/101/110/110/140/1491/1501/146
Myocardial ischaemiaCardiac disorders0/110/100/140/130/101/110/110/140/1490/1501/146
CellulitisInfections and infestations0/110/101/140/130/100/110/110/140/1491/1502/146
PneumoniaInfections and infestations0/110/100/140/130/100/110/111/141/1491/1503/146
Cardiac failureCardiac disorders0/110/100/140/130/100/110/110/144/1493/1505/146
Cardiac failure acuteCardiac disorders0/110/100/140/130/100/110/110/141/1493/1503/146
Cardiac failure congestiveCardiac disorders0/110/100/140/130/100/110/110/143/1493/1503/146
Cardiac failure chronicCardiac disorders0/110/100/140/130/100/110/110/143/1490/1500/146
Angina pectorisCardiac disorders0/110/100/140/130/100/110/110/140/1493/1501/146
Troponin increasedInvestigations0/110/100/140/130/100/110/110/140/1492/1502/146
Most frequent other events
Showing 10 of 44
Most frequent other events
EventDose-escalation Cohort 1: PlaceboDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: PlaceboDose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2Expansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based Titration
HeadacheNervous system disorders0/110/101/145/130/102/110/110/145/1492/1509/146
AstheniaGeneral disorders0/111/103/140/130/100/111/110/142/1492/1502/146
Muscle spasmsMusculoskeletal and connective tissue disorders0/110/100/140/130/102/110/110/140/1490/1501/146
AnaemiaBlood and lymphatic system disorders0/110/100/140/131/100/110/110/141/1490/1500/146
Bundle branch block leftCardiac disorders0/111/100/140/130/100/110/110/140/1491/1500/146
Sinus tachycardiaCardiac disorders0/111/100/140/130/100/110/110/140/1490/1500/146
Skin abrasionInjury, poisoning and procedural complications0/110/100/140/131/100/110/110/140/1490/1500/146
AsthmaRespiratory, thoracic and mediastinal disorders0/111/100/140/130/100/110/110/140/1490/1500/146
HypotensionVascular disorders0/111/100/140/130/101/110/111/143/1491/1505/146
FatigueGeneral disorders0/110/100/140/130/100/110/110/144/14914/1509/146

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dose-escalation Cohort 1: PlaceboDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: PlaceboDose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2Expansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based TitrationTotal
Mean66.5 ± 4.667.7 ± 11.465.3 ± 8.866.7 ± 8.762.1 ± 9.365.1 ± 7.063.8 ± 11.664.3 ± 11.563.7 ± 9.762.8 ± 10.262.7 ± 11.763.4 ± 10.4
Age, Customized
Age, Customized(Participants)Dose-escalation Cohort 1: PlaceboDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: PlaceboDose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2Expansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based TitrationTotal
18 - 64 years34755656828176280
65 - 74 years84465445465250188
75 - 84 years0332013321172376
Sex: Female, Male
Sex: Female, Male(Participants)Dose-escalation Cohort 1: PlaceboDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: PlaceboDose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2Expansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based TitrationTotal
Female2231334230232497
Male99111278812119127125447
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose-escalation Cohort 1: PlaceboDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: PlaceboDose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2Expansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based TitrationTotal
Hispanic or Latino0101101027417
Not Hispanic or Latino111014129111114147143145527
Unknown or Not Reported000000000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose-escalation Cohort 1: PlaceboDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: PlaceboDose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2Expansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based TitrationTotal
American Indian or Alaska Native000000000000
Asian000000002103
Black or African American31000312115834
Mixed Race000100000001
Native Hawaiian or Other Pacific Islander000000000101
White71014121081112136142140502
Other100000000113
Stratification Factor - Atrial Fibrillation/Flutter at Randomization
Stratification Factor - Atrial Fibrillation/Flutter at Randomization(Participants)Dose-escalation Cohort 1: PlaceboDose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2Dose-escalation Cohort 2: PlaceboDose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2Expansion Phase: PlaceboExpansion Phase: Omecamtiv Mecarbil 25 mgExpansion Phase: OM PK-based TitrationTotal
Yes00320123323232107
No1111111110101011117118117437
08

Study locations

101 sites
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Costa Mesa, California 92626, United States
  • Research Site
    Fresno, California 93721, United States
  • Research Site
    Inglewood, California 90301, United States
  • Research Site
    La Jolla, California 92037, United States
  • Research Site
    Los Angeles, California 90033, United States
  • Research Site
    Thousand Oaks, California 91360, United States
  • Research Site
    Tustin, California 92780, United States
  • Research Site
    Danbury, Connecticut 06810, United States
  • Research Site
    Newark, Delaware 19718, United States
  • Research Site
    Atlantis, Florida 33462, United States
  • Research Site
    Aventura, Florida 33180, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Tampa, Florida 33606, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Macon, Georgia 31201, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Auburn, Maine 04210, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Petoskey, Michigan 49770, United States
  • Research Site
    Minneapolis, Minnesota 55415, United States
  • Research Site
    Minneapolis, Minnesota 55417, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Las Vegas, Nevada 89128, United States
  • Research Site
    Bronx, New York 10467, United States
  • Research Site
    Cortlandt Manor, New York 10567, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Greenville, South Carolina 29605, United States
  • Research Site
    Nashville, Tennessee 37232-8802, United States
  • Research Site
    Tullahoma, Tennessee 37388, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Seattle, Washington 98195, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Darlinghurst, New South Wales 2010, Australia
  • Research Site
    Nedlands, Western Australia 6009, Australia
  • Research Site
    Antwerpen, 2020, Belgium
  • Research Site
    Bonheiden, 2820, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Ieper, 8900, Belgium
  • Research Site
    Liege, 4000, Belgium
  • Research Site
    Kazanlak, 6100, Bulgaria
  • Research Site
    Pazardzhik, 4700, Bulgaria
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Sandanski, 2800, Bulgaria
  • Research Site
    Sliven, 8800, Bulgaria
  • Research Site
    Smolyan, 4400, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Edmonton, Alberta T6G 2B7, Canada
  • Research Site
    Winnipeg, Manitoba R2H 2A6, Canada
  • Research Site
    St. Johns, Newfoundland and Labrador A1B 3V6, Canada
  • Research Site
    Halifax, Nova Scotia B3H 3A7, Canada
  • Research Site
    Ottawa, Ontario K1Y 4W7, Canada
  • Research Site
    Montreal, Quebec H3G 1A4, Canada
  • Research Site
    Québec, Quebec G1V 4G5, Canada
  • Research Site
    Sherbrooke, Quebec J1G 2E8, Canada
  • Research Site
    Trois Rivieres, Quebec G8T 7A1, Canada
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Brno, 636 00, Czechia
  • Research Site
    Olomouc, 771 11, Czechia
  • Research Site
    Praha 2, 128 08, Czechia
  • Research Site
    Praha 4, 140 21, Czechia
  • Research Site
    Svitavy, 568 25, Czechia
  • Research Site
    Teplice, 415 29, Czechia
  • Research Site
    Bad Krozingen, 79189, Germany
  • Research Site
    Bad Nauheim, 61231, Germany
  • Research Site
    Berlin, 13353, Germany
  • Research Site
    Dortmund, 44137, Germany
  • Research Site
    Greifswald, 17475, Germany
  • Research Site
    Budapest, 1027, Hungary
  • Research Site
    Budapest, 1125, Hungary
  • Research Site
    Budapest, 1135, Hungary
  • Research Site
    Jaszbereny, 5100, Hungary
  • Research Site
    Zalaegerszeg, 8900, Hungary
  • Research Site
    Brescia, 25125, Italy
  • Research Site
    Pavia, 27100, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Kaunas, 50009, Lithuania
  • Research Site
    Vilnius, 08661, Lithuania
  • Research Site
    Amersfoort, 3813 TZ, Netherlands
  • Research Site
    Groningen, 9713 GZ, Netherlands
  • Research Site
    Utrecht, 3584 CX, Netherlands
  • Research Site
    Bialystok, 15-276, Poland
  • Research Site
    Klodzko, 57-300, Poland
  • Research Site
    Krakow, 31-202, Poland
  • Research Site
    Krakow, 31-501, Poland
  • Research Site
    Lublin, 20-954, Poland
  • Research Site
    Ruda Slaska, 41-703, Poland
  • Research Site
    Warszawa, 04-256, Poland
  • Research Site
    Wroclaw, 50-981, Poland
  • Research Site
    Dudley, DY1 2HQ, United Kingdom
  • Research Site
    Dundee, DD1 9SY, United Kingdom
  • Research Site
    Glasgow, G11 6NT, United Kingdom
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
  • Research Site
    Leicester, LE3 9QP, United Kingdom
  • Research Site
    Liverpool, L14 3PE, United Kingdom

Showing the first 100 of 101 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF Jr, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsanyi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, Honarpour N; COSMIC-HF Investigators. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016 Dec 10;388(10062):2895-2903. doi: 10.1016/S0140-6736(16)32049-9. Epub 2016 Dec 1. PubMed 27914656 ↗
  • Biering-Sorensen T, Minamisawa M, Liu J, Claggett B, Papolos AI, Felker GM, McMurray JJV, Legg JC, Malik FI, Honarpour N, Kurtz CE, Teerlink JR, Solomon SD. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). Eur J Heart Fail. 2021 Jun;23(6):1052-1056. doi: 10.1002/ejhf.2181. Epub 2021 May 5. No abstract available. PubMed 33826209 ↗
  • Biering-Sorensen T, Minamisawa M, Claggett B, Liu J, Felker GM, McMurray JJV, Malik FI, Abbasi S, Kurtz CE, Teerlink JR, Solomon SD. Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. Circ Heart Fail. 2020 Dec;13(12):e008007. doi: 10.1161/CIRCHEARTFAILURE.120.008007. Epub 2020 Nov 12. No abstract available. PubMed 33176443 ↗
  • Felker GM, Solomon SD, McMurray JJV, Cleland JGF, Abbasi SA, Malik FI, Zhang H, Globe G, Teerlink JR; COSMIC-HF Investigators. Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study. Circ Heart Fail. 2020 Dec;13(12):e007814. doi: 10.1161/CIRCHEARTFAILURE.120.007814. Epub 2020 Nov 12. PubMed 33176437 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2013 to primary completion in Jul 2015, 28 months.

Results were first posted in May 2021, 5 years 9 months after primary completion. A results delay was requested in Mar 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2013
First posted
Feb 8, 2013
StartActual
Feb 26, 2013
Primary completionActual
Jul 22, 2015
CompletionActual
Aug 19, 2015
Results delay requested
Mar 7, 2016
Results first posted
May 17, 2021
Last update
Aug 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01786512
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
Feb 8, 2013
Start date
Feb 26, 2013
Primary completion
Jul 22, 2015
Completion
Aug 19, 2015
Results posted
May 17, 2021
Last update
Aug 12, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omecamtiv mecarbil

Start the discussion